Cardiol Therapeutics Inc.
NASDAQ:CRDLDrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $114.64M
- Beta
- 0.80
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.31M
Average 0.68M
CRDL Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Cardiol Therapeutics Inc.NASDAQ: CRDL
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -CA$9.73M, compared with -CA$8.43M a year earlier. Trailing-twelve-month operating income was -CA$35.62M.
Context
- Operating income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 4 analysts of -CA$36.38M (-6.0%) for the fiscal year ending Dec 2026, a slowdown from the +14.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CA$9.73M-21.2% QoQ
- Last fiscal yearDec 2025
- -CA$34.32M+14.8% YoY
- LTMMar 2026
- -CA$35.62M-1.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -15.5% | — | — |
| 1 year | +14.8% | -6.0% | -20.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
CAD · from the income statement
- Latest · FY2025
- (34.32M) CAD
- Year-over-year change
- +14.8%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (34.32M) | +14.8% |
| FY2024 | 2024-12-31 | (40.28M) | -79.2% |
| FY2023 | 2023-12-31 | (22.47M) | +26.3% |
| FY2022 | 2022-12-31 | (30.49M) | +0.2% |
| FY2021 | 2021-12-31 | (30.57M) | — |
Operating Income vs competitors
How CRDL compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -1.3% is the 5th highest of 10, against a peer median of -8.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$16.04M USD | -30.8% | — | 15278.1% | |
| LTM Mar 2026 | -$22.75M USD | +31.2% | — | 22.3% | |
| LTM Mar 2026 | -$27.81M USD | -11.2% | — | — | |
| LTM Mar 2026 | -$34.74M USD | +20.1% | — | 226.6% | |
| LTM Mar 2026 | -CA$35.62M CAD | -1.3% | — | — | |
| LTM Mar 2026 | -€42.37M EUR | +20.8% | — | 144445.0% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$47.63M USD | +33.8% | — | — |
IMAImageneBio Inc | LTM Mar 2026 | -$55.93M USD | -8.5% | — | — |
| FY2025 | -$58.07M USD | -158.7% | — | 90740.6% | |
| LTM Jun 2025 | -₪72M ILS | -68.2% | -49.0% | 29.6% | |
| Peer median (excluding CRDL) | — | -8.5% | -49.0% | 7752.4% | |
Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 62.27K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 174.26K | 162.23K | 187.38K | 0 | 0 |
| Gross Profit | (112K) | (162.23K) | (187.38K) | 0 | 0 |
| Gross Margin | -179.9% | — | — | — | — |
| Research & Development | 8.59M | 13.99M | 10.73M | 14.01M | 14.02M |
| Selling, General & Admin | 21.86M | 16.34M | 11.55M | 25.89M | 20.2M |
| Operating Expenses | 30.46M | 30.33M | 22.29M | 40.28M | 34.32M |
| Depreciation & Amortization | 174.26K | 162.23K | 187.38K | 162.11K | 101.98K |
| EBITDA | (24.84M) | (22.66M) | (21.04M) | (36.52M) | (33.72M) |
| EBITDA Margin | -39891.0% | — | — | — | — |
| Operating Income | (30.57M) | (30.49M) | (22.47M) | (40.28M) | (34.32M) |
| Operating Margin | -49092.4% | — | — | — | — |
| Interest Income | 106K | 1.24M | 2.04M | 1.19M | 726.4K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.56M | 7.68M | 1.25M | 3.6M | 497.42K |
| Income Before Tax | (25.01M) | (22.82M) | (21.22M) | (36.68M) | (33.82M) |
| Pre-Tax Margin | -40170.9% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (25.01M) | (22.82M) | (21.22M) | (36.68M) | (33.82M) |
| Net Margin | -40170.9% | — | — | — | — |
| EPS (Basic) | (0.73) | (0.49) | (0.44) | (0.51) | (0.39) |
| EPS (Diluted) | (0.73) | (0.49) | (0.44) | (0.51) | (0.39) |
| Weighted Avg Shares | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
| Weighted Avg Shares (Diluted) | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
Cardiol Therapeutics Inc.
NASDAQ:CRDL
Intrinsic Alpha fair value
Locked
Current Price
$0.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.